It is insanely optimistic that we have drugs that can reduce Lp(a) levels by 98% in trials right now.
If they succeed, they could help to crush heart disease and stroke.
Unlike LDL in general, Lp(a) levels are basically entirely genetic in origin and not open to lifestyle intervention. It is also widely accepted that the race differences are down to genes.
These drugs are examples of genetic discovery leading to a group difference fix via tech.
Compared to twenty years ago, kids are eating some types of ultraprocessed foods more and some types less🧵
For example, one thing there's proportionally less of is sugar-sweetened beverage consumption. Meanwhile, there's relatively greater sweet snack consumption.
Overall, the ultraprocessed food (UPF) consumption share is up across young ages to similar degrees.
The increase is definitely there, but it isn't dramatic. For example, going from 61% to 67.5% is an 11% increase in twenty years.
The increase in consumption is not differentiated by the sex of children.
In other words, boys and girls are both eating a bit more ultraprocessed food.
People tend to understand it as an indication that earlier generations were a lot less intelligent than we moderns.
Or if they're read up on the literature, they now think things are reversing.
Both are wrong! Take a look at this chart of Norwegian data:
If you don't understand what those tests are like, here are some example questions:
What we see over time with the Flynn Effect (the increase in IQ scores) and the Reverse Flynn Effect (the more recent decrease in IQ scores) is that both are due to something really boring: people interpreting tests differently than they used to.
The study took place in Germany and was centered on the experiences of 107 people aged 21-40 who lived alone and had earnings between €1,100 and €2,600 per month.
The experiment provided them with €1,200 per month for three full years.
Controls (N = 1,580) earned €10 for sticking with the program and another €30 if they made it the whole way.
There was no attrition in the treatment group, but 29% of the control group dropped out by the end of the study.
Many women have found that they get pregnant more easily after getting on GLP-1 drugs.
But women aren't the only ones noticing improved fertility:
There's now clinical trial evidence that GLP-1s improve sperm parameters.
The largest clinical trial published so far on this subject came out in 2023. It involved 110 men aged 18-35 with metabolic hypogonadism being sorted into one of three conditions:
A: The group seeking fatherhood.
B: The group not seeking fatherhood.
C: The group of already-dads.
The men in Group A were explicitly given the fertility drugs urofollitropin three times a week and human chorionic gonadotropin twice a week.